Icon Plc [ICLR] stock is trading at $335.49, up 1.28%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The ICLR shares have gain 4.04% over the last week, with a monthly amount glided 28.79%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
On 26, February 2024, ICON plc to Present at Upcoming Investor Conferences. In a post published today on Yahoo Finance, ICON plc, (NASDAQ: ICLR) a world-leading clinical research organization powered by healthcare intelligence, today announced that Mr. Brendan Brennan, CFO of ICON plc, will present at the TD Cowen 44th Annual Healthcare Conference on Tuesday, March 5, 2024 at 11:10 am ET and Dr. Steve Cutler, CEO of ICON plc, will present at the Barclays 26th Annual Global Healthcare Conference on Tuesday, March 12, 2024, at 2:05 pm ET.
From an analyst’s perspective:
Icon Plc [NASDAQ: ICLR] stock has seen the most recent analyst activity on December 15, 2023, when Truist initiated its Buy rating and assigned the stock a price target of $357. Previously, TD Cowen started tracking the stock with Outperform rating on September 13, 2023, and set its price target to $306. On January 17, 2023, upgrade upgraded it’s rating to Overweight and revised its price target to $260 on the stock. Barclays upgraded its rating to a Overweight. BofA Securities upgraded its rating to a Buy and reduced its price target to $260 on November 09, 2022. UBS started tracking with a Buy rating for this stock on September 07, 2022, and assigned it a price target of $270. In a note dated August 25, 2022, Credit Suisse initiated an Neutral rating and provided a target price of $260 on this stock.
Icon Plc [ICLR] stock has fluctuated between $181.92 and $332.95 over the past year. Currently, Wall Street analysts expect the stock to reach $241.25 within the next 12 months. Icon Plc [NASDAQ: ICLR] shares were valued at $335.49 at the most recent close of the market. An investor can expect a potential drop of -28.09% based on the average ICLR price forecast.
Analyzing the ICLR fundamentals
Icon Plc [NASDAQ:ICLR] reported sales of 8.12B for the trailing twelve months, which represents a growth of 5.31%. Gross Profit Margin for this corporation currently stands at 0.28% with Operating Profit Margin at 0.12%, Pretax Profit Margin comes in at 0.08%, and Net Profit Margin reading is 0.08%. To continue investigating profitability, this company’s Return on Assets is posted at 0.04, Equity is 0.07 and Total Capital is 0.07. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.41.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 328.66 points at the first support level, and at 321.82 for the second support level. However, for the 1st resistance point, the stock is sitting at 339.02, and for the 2nd resistance point, it is at 342.54.
Icon Plc [ICLR] reported earnings per share of $3.46 for its fiscal quarter that ended on 12/30/2023. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of $3.44/share, meaning a difference of $0.02 and a surprise factor of 0.60%. By comparison, the stated earnings for the previous quarter ended on 9/29/2023 were $3.3 per share as compared to estimates of $3.28 per share, a difference of $0.02 representing a surprise of 0.60%.
Ratios To Look Out For
For context, Icon Plc’s Current Ratio is 1.21. Also, the Quick Ratio is 1.21, while the Cash Ratio stands at 0.13. Considering the valuation of this stock, the price to sales ratio is 3.41, the price to book ratio is 3.00 and price to earnings (TTM) ratio is 45.41.
